Aytu Biopharma (AYTU) Finished Goods (2019 - 2026)

Aytu Biopharma (AYTU) has 8 years of Finished Goods data on file, last reported at $4.0 million in Q1 2026.

• On a quarterly basis, Finished Goods fell 52.24% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 52.24% decrease from a year earlier, with the FY2025 full-year figure at $8.9 million, up 45.33% from the prior year.
• Finished Goods for Q1 2026 stood at $4.0 million, down from $5.6 million in the prior quarter.
• Over the last five years, Finished Goods for AYTU reached as high as $9.9 million in Q1 2022 and fell as low as $4.0 million in Q1 2026.
• Historically, Finished Goods has averaged $7.6 million across 5 years, with a median of $7.7 million in 2023.
• Across the five-year window, Finished Goods soared 45.33% in 2025 and tumbled 52.24% in 2026, its largest moves.
• Year by year, Finished Goods stood at $8.4 million in 2022, then climbed by 3.73% to $8.7 million in 2023, then dropped by 13.66% to $7.5 million in 2024, then decreased by 24.81% to $5.6 million in 2025, then declined by 28.22% to $4.0 million in 2026.
• Per Business Quant data, the three most recent Finished Goods figures were $4.0 million in Q1 2026, $5.6 million in Q4 2025, and $7.9 million in Q3 2025.